Tenover Fred C, Goff Debra A
Cepheid, Sunnyvale, California, USA.
College of Pharmacy, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Open Forum Infect Dis. 2023 Mar 29;10(4):ofad176. doi: 10.1093/ofid/ofad176. eCollection 2023 Apr.
Colonization with multidrug-resistant organisms (MDROs) is a risk factor for subsequent infection. Surveillance for MDROs, including methicillin-resistant , vancomycin-resistant enterococci, extended-spectrum beta-lactamase-producing Enterobacterales, and carbapenemase-producing organisms, is commonly conducted in hospitals to prevent spread of MDROs, in part to reduce the potential for additional infections. Although colonization is a risk factor for infection, data on colonization with various MDROs are often not considered when selecting anti-infective therapy. There are conflicting data on the strength of the positive and negative predictive values of the colonization test results to guide therapeutic strategies. Defining therapeutic strategies for patients with complicated or drug-resistant infections or to select antimicrobial prophylaxis before performing prostate biopsies often falls under the purview of the antimicrobial stewardship team. Should colonization data, which are often present in the patient's medical record from routine infection prevention measures, be reviewed before selecting therapy for infections or for prophylaxis? In this perspective, we will explore the intersection of infection control and antimicrobial stewardship activities.
多重耐药菌(MDROs)定植是随后发生感染的一个危险因素。医院通常会对MDROs进行监测,包括耐甲氧西林金黄色葡萄球菌、耐万古霉素肠球菌、产超广谱β-内酰胺酶的肠杆菌科细菌以及产碳青霉烯酶的微生物,以防止MDROs传播,部分原因是为了降低额外感染的可能性。虽然定植是感染的一个危险因素,但在选择抗感染治疗时,通常不会考虑各种MDROs定植的数据。关于定植检测结果指导治疗策略的阳性和阴性预测值的强度,存在相互矛盾的数据。为患有复杂或耐药感染的患者确定治疗策略,或在进行前列腺活检前选择抗菌药物预防措施,通常属于抗菌药物管理团队的职责范围。在为感染或预防选择治疗方法之前,是否应该查看通常存在于患者病历中的来自常规感染预防措施的定植数据?在这篇观点文章中,我们将探讨感染控制与抗菌药物管理活动的交叉点。